General Clinical Chemistry Analyzers and Accessories
Abcam ABT-199 (Venetocla x ), Bcl-2 inhibitor., 5MG
MW 868.4 Da, Purity >98%. Potent, selective Bcl-2 inhibitor (Ki <0.01 nM) that inhibits the growth of Bcl-2–dependent tumors while sparing platelets. Bcl-2–specific BH3 mimetic. Promising agent in the treatment of chronic lymphocytic leukaemic and estrogen receptor-positive breast cancer.
The product is subject to the following: Abcam Restricted Use Statement
AdipoGen Cyclotrisiloxanol pentamethyl
Chemical. CAS 106916-50-1. Formula C5H16O4Si3. MW 224.43. Organosilicon compounds are organometallic compounds containing carbon-silicon bonds. Organosilicon compounds are widely encountered in commercial products. Most common are antifoamers, caulks sealant, adhesives, and coatings made from silicones. Other important uses include agricultural and plant control adjuvants commonly used in conjunction with herbicides and fungicides. Several organosilicon compounds have been investigated as pharmaceuticals.
AdipoGen N4-Acetylsulfadimethoxine
Chemical. CAS 555-25-9. Formula C14H16N4O5S. MW 352.37. Synthetic Metabolite of the long-acting sulfonamide antibiotic sulfadimethoxine, used in freshwater aquaculture. Sulfonamide that is benzenesulfonamide substituted by an acetylamino group at position 4 and a 4,6-dimethoxy-pyrimidin-2-yl group at the nitrogen atom. Compound can be used as analytical reference material.
Abcam PF-573228, 50MG
MW 491.5 Da, Purity >=98%. Potent and selective FAK inhibitor (IC₅₀ = 4 nM versus recombunant catalytic fragent). Blocks FAK Tyr397phosphorylation in cultured cells (IC₅₀ = 30–100 nM). Shows 50 - 250-fold selectivity for FAK aginst a panel of 40 recombinant kinases. Inhibits chemotactic and haptotactic cell migration.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SCR7 pyrazine, NHEJ inhibitor, 25MG
MW 332.4 Da, Purity >98%. Small molecule nonhomologous end-joining (NHEJ) inhibitor. SCR7 analog. Enhances CRISPR-Cas9-mediated homology-directed repair (HDR) efficiency in vitro.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Elvitegravir, quinolone HIV integrase inhibitor, 50MG
MW 447.9 Da, Purity >99%. Elvitegravir is an inhibitor of HIV integrase. It inhibits HIV integrase from HIV 1 IIIB (IC₅₀ = 0.7 nM), HIV 2 EHO (IC₅₀ = 2.8 nM) and HIV-2 ROD (IC₅₀ = 1.1 nM) in cell free assays. Elvitegravir blocks integration of HIV cDNA via inhibition of DNA strand transfer. Active against a range of HIV sub-types and against mulit-drug resistant clinical isolates. Potent (IC₅₀ range = 0.21 - 1.15 nM) HIV antiviral activity in various cell-based assays.
The product is subject to the following: Abcam Restricted Use Statement
AdipoGen Coumaphos
Chemical. CAS 56-72-4. Formula C14H16ClO5PS. MW 362.77. Synthetic. An organophosphate pesticide. Acetylcholinesterase AChE inhibitor in the nervous system with subsequent accumulation of toxic levels of acetylcholine ACh. Selective insecticide used for control of a wide variety of livestock insects, including cattle grubs, screw-worms, lice, scabies, flies and ticks. Also used against ectoparasites, which are insects that live on the outside of host animals such as sheep, goats, horses, pigs and poultry. Not used on agricultural or residential plants.
Abcam Alvespimycin (17-DMAG) hydrochloride, 10MG
MW 653.2 Da, Purity >99%. A potent Hsp90 inhibitor (IC₅₀ = 62 nM), can bind to the ATP-binding motif and inhibit the protein chaperoning activity.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Dabrafenib, mutant B-Raf V600E inhibitor, 25MG
MW 519.6 Da, Purity >98%. Potent, ATP-competitive mutant B-Raf V600E inhibitor (IC50 = 0.7 nM), with selectivity versus wild-type B-Raf (IC50 = 5.2 nM) and c-RAf (IC50 = 6.3 nM) in cell-free assays. Antitumor activity *in vivo* in mouse models of B-Raf V600E melanoma.
The product is subject to the following: Abcam Restricted Use Statement
Abcam V x -745, p38 alpha MAPK inhibitor, 5MG
MW 436.3 Da. Potent, selective p38 alpha MAPK inhibitor (IC₅₀ = 10 nM), with 20-fold selectivity over p38 beta and 1000-fold selectivity over closely related kinases, ERK1 and JNK1-3.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LMK 235, HDAC inhibitor, 25MG
MW 294.35 Da, Purity >98%. Highly potent and selective HDAC inhibitor. Greater potency for HDAC4 and HDAC5 (IC₅₀ = 11.9 and 4.2 nM, respectively) than other HDAC family members (IC₅₀ values = HDAC1 320 nM, HDAC2 881 nM, HDAC6 55.7 nM, and HDAC8 1278 nM. Demonstrates inhibitor activity in human ovarian cell lines (IC₅₀ =0.49μM) and cisplatin resistant cell lines (IC₅₀ = 0.32μM).
The product is subject to the following: Abcam Restricted Use Statement
Abcam G10, STING signaling activator, 5MG
MW 430.9 Da, Purity >98%. G10 is an indirect activator or stimulator of interferon genes (STING) signaling. It induces transcription of genes dependent on IRF3 and IFN, which are activated by STING, but has no effect on non-STING activated NF-κB-dependent transcription of IL-8, IL-1β, or MIP-1α in human fibroblasts. However, G10 does increase expression of NF-κB-dependent genes in human peripheral blood mononuclear cells (PBMCs) and human umbilical microvascular endothelial cells (HUMECs). In vitro, it prevents replication of the chikungunya and Venezuelan equine encephalitis alphaviruses (IC₉₀s = 8.01 and 24.57 μM, respectively). G10 (100 μM) increases phosphorylation of IRF3, which is lost in cells lacking STING.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Miglustat hydrochloride, 1MG
MW 255.74 Da, Purity >=98%. An inhibitor of the N-linked oligosaccharide processing enzymes α-glucosidase I and II. It inhibits rat testicular enzymes ceramide-glucosyltransferase and beta-glucosidase 2 with IC₅₀ values of 32 and 81 μM respectively. Miglustat is used for the treatment of type 1 Gaucher's disease. It is an inhibitor of HIV replication in vitro. It shows activity against SARS-CoV-2 in vitro with EC₅₀ values in the micromolar range.
The product is subject to the following: Abcam Restricted Use Statement
Abcam CHIR-124, 5MG
MW 419.9 Da, Purity >98%. Novel and potent Chk1 inhibitor (IC₅₀ = 0.3 nM), 2,000-fold more potent than Chk2 (IC₅₀ = 0.7 μM). Also, potently targets other kinases such as FLT3 (IC₅₀ = 5.8 nM), PDGFR (IC₅₀ = 6.6 nM), GSK-3 (IC₅₀ = 23.3 nM) and Fyn (IC₅₀ = 98.8 nM) .
The product is subject to the following: Abcam Restricted Use Statement